Pre-Operative fSRS for Brain Metastases
Improving Outcomes in Patients With Metastatic Cancer to the Brain With Pre-Operative Fractionated Radiosurgery (fSRS): A Pilot Study
This pilot study investigates a new approach for patients with metastatic cancer that has spread to the brain (brain metastases) who are already planned to receive both fractionated stereotactic radiosurgery (fSRS) and brain surgery as standard treatment for their condition. Usually, surgery comes first, followed by radiation. However, post-operative radiation can sometimes lead to the cancer returning in the area, spreading to the brain's lining (LMD), or causing side effects from radiation (RN). This study hypothesizes that delivering fSRS before surgery may improve outcomes by enabling more accurate targeting, reducing tumor spillage, and potentially decreasing RN, while improving treatment compliance. The study is specifically testing the sequence of these two standard treatments.
This is a single-arm, prospective study enrolling 12 adult participants (age >18) with 1-5 brain metastases, where one main tumor (between 2.0-5.0 cm diameter) requires surgical resection. Participants will receive fSRS (27 Gy in 3 fractions) approximately one week prior to surgery, as part of the study's approach. Throughout the study, participants will also have regular brain MRI scans to monitor their condition and complete tests to check memory and thinking skills (like the MoCA test) at various points.
The main goal is to see how well the cancer is controlled at the surgery site (called local freedom from progression, or FFP) over 6, 12, 18, and 24 months post-operatively. Secondary outcomes include rates of LMD and RN. Safety (adverse events, toxicities) will be continuously monitored by an independent Data Safety Monitoring Committee (DSMC). Each participant will be in the study for 2 years.
This research aims to provide preliminary data to inform future larger, randomized trials, ultimately improving treatment strategies for patients with metastatic brain cancer.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
New York
-
New York, New York, Estados Unidos, 10075
- Lenox Hill Hospital, Northwell Health
-
Investigador principal:
- A. Gabriella Wernicke, MD, MS
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Patient is ≥18 years old.
- Radiographic confirmation of 1-5 brain metastases by MRI with contrast obtained within 4 weeks prior to registration. One of these must be an index lesion requiring surgical resection.
- The maximum diameter of the index lesion, as measured on any orthogonal plane (axial, sagittal, coronal) on the post-contrast MRI, must be ≥2.0 cm and ≤5.0 cm.
- Documented pathological diagnosis of active or history of invasive cancer within the past 5 years.
- All brain metastases must be located ≥5 mm from the optic chiasm and outside the brainstem.
- Patient can medically tolerate surgery and fSRS. The treating surgeon must deem the index lesion an appropriate target for safe resection.
- Karnofsky Performance Status (KPS) ≥50 within 14 days prior to registration.
- A negative urine or serum pregnancy test (for individuals of childbearing potential) ≤14 days prior to registration.
- Patient or legally authorized representative provides study-specific informed consent before study entry. For patients treated in the U.S., authorization permitting release of personal health information is also required.
Exclusion Criteria:
- Previous cranial radiotherapy, including whole-brain radiotherapy or stereotactic radiosurgery (SRS), to the planned resection site (index lesion). Repeat radiosurgery to the same location/lesion is not permitted on this protocol.
Note: Prior or current fSRS/SRS to other non-index lesions is allowed.
- Evidence of leptomeningeal disease.
- Any contraindication or inability to undergo MRI with contrast.
- Planned administration of cytotoxic chemotherapy or tyrosine/multi-kinase inhibitors within 3 days prior to, on the day of, or within 3 days after the completion of fSRS.
Note: Chemotherapy and immunotherapy outside of this window are allowed.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Pre-Operative fSRS Followed by Re-Section
This arm consists of all enrolled participants who will receive fractionated stereotactic radiosurgery (fSRS) prior to neurosurgical resection of their brain metastasis. This approach investigates a modified sequence of two standard-of-care treatments for this condition, aiming to evaluate its safety and efficacy. |
Pre-operative fSRS to a dose of 27 Gy in 3 fractions will be delivered to the index lesion every other day. These radiation treatments will be completed within 1 week (+/- 5 days) prior to surgical resection. This is a standard radiation procedure for brain metastases. Surgical removal of the brain metastasis (index lesion) performed after completion of pre-operative fSRS. This is a standard surgical procedure for brain metastases.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Local Freedom from Progression (FFP) within the Resection Cavity
Prazo: 6, 12, 18, and 24 Months Post-Operative
|
The absence of new nodular contrast enhancement 2 mm or less from the resection cavity. |
6, 12, 18, and 24 Months Post-Operative
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Incidence of Leptomeningeal Disease (LMD)
Prazo: From post-operative MRI (48-72 hours after surgery) through every 3 months for 2 years
|
Documented incidence of LMD on brain MRI imaging |
From post-operative MRI (48-72 hours after surgery) through every 3 months for 2 years
|
|
Incidence of Radiation Necrosis (RN)
Prazo: From post-operative (48-72 hours after surgery) through every 3 months for 2 years
|
Documented incidence of RN on brain MRI imaging |
From post-operative (48-72 hours after surgery) through every 3 months for 2 years
|
|
Change in Neurocognitive Function
Prazo: Baseline, Post-Operative Visit, and Every 3 Months for 2 Years
|
Assessed using the Montreal Cognitive Assessment (MoCA) score |
Baseline, Post-Operative Visit, and Every 3 Months for 2 Years
|
Outras medidas de resultado
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Correlation of Pathologic Information Between Primary Cancer and Resected Brain Metastasis
Prazo: Between Surgery and Post-Operative Visit
|
Comparison of pathological characteristics of resected brain metastasis with the primary tumor |
Between Surgery and Post-Operative Visit
|
|
Correlation of Extent of Surgical Resection with Survival Outcomes
Prazo: From study registration until 2 years post-operative or death
|
Evaluation of the Association between extent of surgical resection and Progression-Free Survival (PFS) and Overall Survival (OS) |
From study registration until 2 years post-operative or death
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Publicações e links úteis
Publicações Gerais
- Shepard MJ, Sheehan JP. The Choice of Postoperative Stereotactic Radiosurgery After Resection of an Isolated Brain Metastasis. Int J Radiat Oncol Biol Phys. 2019 Dec 1;105(5):940. doi: 10.1016/j.ijrobp.2018.05.081. Epub 2019 Oct 24. No abstract available.
- Mahajan A, Ahmed S, McAleer MF, Weinberg JS, Li J, Brown P, Settle S, Prabhu SS, Lang FF, Levine N, McGovern S, Sulman E, McCutcheon IE, Azeem S, Cahill D, Tatsui C, Heimberger AB, Ferguson S, Ghia A, Demonte F, Raza S, Guha-Thakurta N, Yang J, Sawaya R, Hess KR, Rao G. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017 Aug;18(8):1040-1048. doi: 10.1016/S1470-2045(17)30414-X. Epub 2017 Jul 4.
- Palmer JD, Perlow HK, Matsui JK, Ho C, Prasad RN, Liu K, Upadhyay R, Klamer B, Wang J, Damante M, Ghose J, Blakaj DM, Beyer S, Grecula J, Arnett A, Thomas E, Chakravarti A, Lonser R, Hardesty D, Prevedello D, Prabhu R, Elder JB, Raval RR. Fractionated pre-operative stereotactic radiotherapy for patients with brain metastases: a multi-institutional analysis. J Neurooncol. 2022 Sep;159(2):389-395. doi: 10.1007/s11060-022-04073-w. Epub 2022 Jun 25.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças Cerebrais
- Doenças do Sistema Nervoso Central
- Doenças do Sistema Nervoso
- Processos Patológicos
- Neoplasias por local
- Neoplasias
- Processos Neoplásicos
- Neoplasias do Sistema Nervoso
- Neoplasias do Sistema Nervoso Central
- Condições Patológicas, Sinais e Sintomas
- Neoplasia Metástase
- Neoplasias Cerebrais
Outros números de identificação do estudo
Outros números de identificação do estudo
- 26-0403
- 23-004 (Outro identificador: Northwell Health Cancer Institute)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
A formal plan for sharing individual participant data (IPD) has not been developed or approved for this pilot study. Participant confidentiality and privacy are strictly maintained, and study data will be transmitted and stored internally at the Northwell Health Cancer Institute (NHCI) in a de-identified format for statistical analysis and scientific reporting. Results will be disseminated through publications that do not contain identifying information.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .